Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 11/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 10/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 2/20 | 1.00 |
| ▸ | CSNK1A1L | Q8N752 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.75 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.75 |
| ▸ | GCGR | P47871 | 9/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.75 |
| ▸ | FRK | P42685 | 2/20 | 0.75 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.75 |
| ▸ | GSK3B | P49841 | 2/20 | 0.75 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.75 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.75 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4336547 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL9201148 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| Hydrochloric Acid SCHEMBL16566835 | 0.99 | MAPK14 (0.98) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL4552997 | 0.88 | ALOX5 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL5698563 | 0.88 | ALOX5 (0.78) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL6930802 | 0.87 | ALOX5 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL178158 | 0.87 | MAPK11 (0.77) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL19868925 | 0.87 | MAPK11 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL15075603 | 0.87 | MAPK11 (1.00) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D | |
| SCHEMBL7484511 | 0.86 | ALOX5 (0.76) | MAPK14MAPK11ALOX5CSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3111937-B1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2020-06-17 | — | — | EP | claimed |
| US-20180043014-A1 | Compositions Using Antibodies Directed to GPNMB and Uses Thereof | CURAGEN CORPORATION | 2018-02-15 | — | — | US | claimed |
| US-20170349880-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | Université de Lausanne (CH) | 2017-12-07 | — | — | US | claimed |
| EP-3233114-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | Université de Lausanne (CH) | 2017-10-25 | — | — | EP | claimed |
| WO-2016096903-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | Université de Lausanne (CH) | 2016-06-23 | — | — | WO | claimed |
| EP-3034092-A1 | Adoptive immunotherapy for treating cancer | Université de Lausanne (CH) | 2016-06-22 | — | — | EP | claimed |
| US-9358225-B2 | Method for treating neurodegeneration using a p38MAPK inhibitor | BACH PHARMA, INC. (US) | 2016-06-07 | — | — | US | claimed |
| US-20140314780-A1 | Compositions Using Antibodies Directed to GPNMB and Uses Thereof | CURAGEN CORPORATION | 2014-10-23 | — | — | US | claimed |
| US-20140303212-A1 | METHOD FOR TREATING NEURODEGENERATION USING A p38MAPK INHIBITOR | Occhiuti & Rohlicek LLP | 2014-10-09 | — | — | US | claimed |
| WO-2014145472-A2 | A METHOD FOR TREATING NEURODEGENERATION USING A P38MAPK INHIBITOR | WONG PAUL K Y (US) | 2014-09-18 | — | — | WO | claimed |
| US-20130156784-A1 | Compositions Using Antibodies Directed To GPNMB And Uses Thereof | JEFFERS MICHAEL (US) | 2013-06-20 | — | — | US | claimed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250302883-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| WO-2006118914-A2 | METHODS OF INCREASING PROLIFERATION OF ADULT MAMMALIAN CARDIOMYOCYTES THROUGH P38 MAP KINASE INHIBITION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060193920-A1 | NANOPARTICULATE COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2006-08-31 | — | — | US | disclosed |
| EP-1490025-A2 | NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS | Elan Pharma International Limited (IE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080024-A2 | NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | disclosed |
| US-20030181411-A1 | Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer | ELAN PHARMA INTERNATIONAL LTD. | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193920-A1 | NANOPARTICULATE COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE INHIBITORS | MAP3K1, MAP3K6, MAP3K2 | MAPK14 31/4885MAPK11 53/4885ALOX5 3909/4885 |
| US-20170349880-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | ICOS, IL2, PBK | MAPK14 4567/4885MAPK11 4429/4885ALOX5 1047/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | MAPK14 2042/4885MAPK11 653/4885ALOX5 4683/4885 |
| US-20030181411-A1 | Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer | PACSIN2, MAP3K20, MAP3K2 | MAPK14 43/4885MAPK11 304/4885ALOX5 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.